Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 8, 2015, Pages 1167-1173

  Marcus, Julia L ^a   Chao, Chun ^a   Leyden, Wendy A ^a   Xu, Lanfang ^a   Yu, Jeanette ^a   Horberg, Michael A ^b   Klein, Daniel ^a   Towner, William J ^a   Quesenberry, Charles P ^a   Abrams, Donald I ^c,d   Silverberg, Michael J ^a  

^a KAISER PERMANENTE   (United States)

^b Mid Atlantic Permanente Research Institute   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANUS CANCER; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK FACTOR; SMOKING; SURVIVAL RATE; COMPLICATION; HIV INFECTIONS; MORTALITY; NEOPLASM; SURVIVAL ANALYSIS;

ADULT; AGED; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84937780181     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1079     Document Type: Article

References (43)

1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-62.
2. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009;52:611-22.
3. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187-94.
4. Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. Aids 2009;23:41-50.
5. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-36.
6. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
7. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with andwithout a known infectious cause. Aids 2009;23:2337-45.
8. Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. Aids 2011;25:691-700.
9. Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fatkenheuer G, et al. Non-AIDS defining cancers in the D:A:D Study-time trends and predictors of survival: a cohort study. BMC Infect Dis 2013;13:471.
10. Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008;22:489-96.
11. Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, et al. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDSdefining malignancies. Int J Cancer 2012;130:2990-6.
12. Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, et al. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an Italian multicenter study. PLoS One 2014;9:e94768.
13. Maso LD, Suligoi B, Franceschi S, Braga C, Buzzoni C, Polesel J, et al. Survival after cancer in italian persons with AIDS, 1986-2005: a population-based estimation. J Acquir Immune Defic Syndr 2014;66:428-35.
14. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005;39:293-9.
15. Coghill AE, Newcomb PA, Madeleine MM, Richardson BA, Mutyaba I, Okuku F, et al. Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS 2013;27:2933-42.
16. Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr 2010;55:510-5.
17. Sigel K, Crothers K, Dubrow R, Krauskopf K, Jao J, Sigel C, et al. Prognosis in HIV-infected patients with non-small cell lung cancer. Br J Cancer 2013;109:1974-80.
18. Legarth R, Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Anal carcinoma in HIV-infected patients in the period 1995-2009: a Danish nationwide cohort study. Scand J Infect Dis 2013;45:453-9.
19. Browning KK, WewersME, Ferketich AK, Diaz P. Tobacco use and cessation in HIV-infected individuals. Clin Chest Med 2013;34:181-90.
20. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010;14:824-35.
21. Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 2014;32:2344-50.
22. Suneja G, Shiels MS, Melville SK, Williams MA, Rengan R, Engels EA. Disparities in the treatment and outcomes of lung cancer among HIVinfected individuals. Aids 2013;27:459-68.
23. Cutrell J, Bedimo R. Non-AIDS-defining cancers among HIV-infected patients. Curr HIV/AIDS Rep 2013;10:207-16.
24. Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012;55:1228-35.
25. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2551-9.
26. Adamo M, Dickie L, Ruhl J. 2014 SEER program coding and staging manual. Bethesda, MD: NCI; 2014.
27. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010;102:1584-98.
28. Rengan R, Mitra N, Liao K, Armstrong K, Vachani A. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 2012;13:1203-9.
29. Reekie J, Kosa C, Engsig F, Monforte A, Wiercinska-Drapalo A, Domingo P, et al. Relationship between current level of immunodeficiency and nonacquired immunodeficiency syndrome-defining malignancies. Cancer 2010;116:5306-15.
30. Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2011;52:1458-65.
31. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56:69-83.
32. Grivennikov SI, Greten FR, KarinM. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
33. Guo HG, Pati S, Sadowska M, Charurat M, Reitz M. Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. J Virol 2004;78:9336-42.
34. Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, et al. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem 2003;278:12310-8.
35. Corallini A, Campioni D, Rossi C, Albini A, Possati L, Rusnati M, et al. Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. Aids 1996; 10:701-10.
36. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, et al. Delayed diagnosis and elevated mortality in an urban populationwith HIV and lung cancer: implications for patient care. JAcquir Immune Defic Syndr 2006;43:47-55.
37. Demopoulos BP, Vamvakas E, Ehrlich JE, Demopoulos R. Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Arch Pathol Lab Med 2003;127: 589-92.
38. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer 2009;8:215-9.
39. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010;153:452-60.
40. Marcus JL, Chao CR, Leyden WA, Xu L, Klein DB, Horberg MA, et al. Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr 2014;66:495-502.
41. Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012;16: 37-41.
42. Gordon N. How does the adult Kaiser Permanente Membership in Northern California compare with the larger community? [Internet]; 2006 [cited 2015 Jan 29]. Available from: .
43. California Department of Public Health, Office of AIDS [Internet]. 2010 Quarterly HIV/AIDS statistics; 2010 [cited 2015 Jan 29]. Available from: .